Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG
2021 · Co-Development · $1.1B · Complete
Announcement Sentiment
82
Strongly positive
Vertex and CRISPR amended their CTX001 collaboration so Vertex leads global development, manufacturing and commercialization with a 60/40 profit/cost split (Vertex 60%). CRISPR received $900M upfront and is eligible for $200M upon first regulatory approval, increasing Vertex's program economics by 10 percentage points.
Key facts
AnnouncedApr 05, 2021
Deal value$1.1B
Deal typeCo-Development
Therapeutic areaSickle cell disease and transfusion-dependent beta-thalassemia
IndicationsSickle cell disease and transfusion-dependent beta-thalassemia
Key assetsCTX001 (exagamglogene autotemcel; later Casgevy)